Exosomal compositions and methods for the treatment of disease

Abstract

An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.

What is claimed is: 
     
         1 . An exosomal composition, comprising a therapeutic agent selected from a phytochemical agent, a chemotherapeutic agent, and a Stat3 inhibitor, the therapeutic agent being encapsulated by an exosome. 
     
     
         2 . The exosomal composition of  claim 1 , where the therapeutic agent is a phytochemical agent selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin. 
     
     
         3 . The exosomal composition of  claim 2 , wherein the phytochemical agent is curcumin. 
     
     
         4 . The exosomal composition of  claim 1 , wherein the therapeutic agent is a Stat3 inhibitor. 
     
     
         5 . The exosomal composition of  claim 4 , wherein the Stat3 inhibitor is JSI-124. 
     
     
         6 . The exosomal composition of  claim 1 , wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         7 . The exosomal composition of  claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol. 
     
     
         8 . The exosomal composition of  claim 1 , wherein the exosome is isolated from a cell. 
     
     
         9 . The exosomal composition of  claim 8 , wherein the cell is a cancer cell. 
     
     
         10 . The exosomal composition of  claim 9 , wherein the cancer cell is selected from a lymphoma cell, an adenocarcinoma cell, and a breast cancer cell. 
     
     
         11 . A pharmaceutical composition, comprising an exosomal composition according to  claim 1  and a pharmaceutically-acceptable vehicle, carrier, or excipient. 
     
     
         12 . A method for treating an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of an exosomal composition comprising a therapeutic agent selected from a phytochemical agent and a Stat3 inhibitor, the therapeutic agent being encapsulated by an exosome. 
     
     
         13 . The method of  claim 12 , wherein the therapeutic agent is a phytochemical agent selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin. 
     
     
         14 . The method of  claim 13 , wherein the phytochemical agent is curcumin. 
     
     
         15 . The method of  claim 12 , wherein the therapeutic agent is a Stat3 inhibitor. 
     
     
         16 . The method of  claim 15 , wherein the Stat3 inhibitor is JSI-124. 
     
     
         17 . The method of  claim 12 , wherein the inflammatory disorder is a brain-related inflammatory disorder. 
     
     
         18 . The method of  claim 17 , wherein the exosomal composition is administered intranasally. 
     
     
         19 . The method of  claim 12 , wherein the inflammatory disorder is an autoimmune disease. 
     
     
         20 . The method of  claim 19 , wherein the autoimmune disorder is selected from the group consisting of lupus, rheumatoid arthritis, and autoimmune encephalomyelitis. 
     
     
         21 . The method of  claim 12 , wherein administering the exosomal composition reduces an amount of an inflammatory cytokine in a subject. 
     
     
         22 . The method of  claim 21 , wherein the inflammatory cytokine is selected from the group consisting of interleukin-1β, tumor necrosis factor-a, and interleukin-6. 
     
     
         23 . A method for treating a cancer, comprising administering to a subject in need thereof an effective amount of an exosomal composition comprising a therapeutic agent selected from a phytochemical agent, a chemotherapeutic agent, and a Stat3 inhibitor, the therapeutic agent being encapsulated by an exosome. 
     
     
         24 . The method of  claim 23 , wherein the cancer is selected from the group consisting of skin cancer, head and neck cancer, colon cancer, breast cancer, brain cancer, and lung cancer. 
     
     
         25 . The method of  claim 23 , wherein the cancer is a brain cancer. 
     
     
         26 . The method of  claim 25 , wherein the brain cancer is a glioma. 
     
     
         27 . The method of  claim 23 , where the therapeutic agent is a phytochemical agent selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin. 
     
     
         28 . The method of  claim 27 , wherein the phytochemical agent is curcumin. 
     
     
         29 . The method of  claim 23 , wherein the therapeutic agent is a Stat3 inhibitor. 
     
     
         30 . The method of  claim 29 , wherein the Stat3 inhibitor is JSI-124. 
     
     
         31 . The method of  claim 23 , wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         32 . The method of  claim 31 , wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol. 
     
     
         33 . The method of  claim 23 , wherein the exosomal composition is administered intranasally, orally, or intratumorally.